Evenity (Romosozumab) Geriatric (65+) Caregiver Administration Guidance

What Romosozumab Is and Why Geriatric Patients Need Caregiver Help

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein that normally suppresses bone formation. By blocking sclerostin, the drug simultaneously increases bone formation and decreases bone resorption, a dual mechanism no other approved osteoporosis agent shares. The FDA approved romosozumab in April 2019 for postmenopausal women with osteoporosis at high fracture risk.

Why Age 65 Amplifies Practical Barriers

Adults over 65 face specific physical barriers that make self-injection unreliable. Arthritis, reduced grip strength, tremor, and diminished visual acuity each impair the fine-motor control required to activate a prefilled syringe correctly. A 2020 analysis in Osteoporosis International found that injection-technique errors in older adults administered subcutaneous biologics at home correlated strongly with reduced therapeutic adherence.

The treatment window is exactly 12 months. Missing or incorrectly administering doses within that window forfeits bone density gains that cannot be recovered by extending the course. That urgency makes caregiver competency non-negotiable.

The Dual-Injection Requirement

Each monthly dose consists of two separate 105 mg prefilled syringes administered back-to-back at the same visit. Caregivers must understand that both syringes constitute a single dose. Administering only one syringe delivers half the approved dose and should be reported to the prescribing clinician the same day. The FDA prescribing information states both injections must be completed consecutively, and the patient should remain seated or lying down for at least five minutes afterward to monitor for syncope or vasovagal response, a real concern in older adults with orthostatic hypotension.

Storage and Handling Before Injection

Proper storage directly affects drug stability and patient safety. Romosozumab degrades if frozen or left at room temperature for extended periods. The following rules apply without exception.

Temperature Requirements

Store prefilled syringes at 2 to 8 degrees Celsius in the original carton. Once removed from refrigeration, syringes may be kept at room temperature (up to 25 degrees Celsius) for a maximum of 30 days. After 30 days at room temperature, discard the syringe even if medication remains inside. Never freeze. If the syringe has been frozen accidentally, discard it and contact the specialty pharmacy for replacement.

Pre-Injection Visual Inspection

Before each injection, the caregiver should hold the syringe up to a light source and confirm the solution is clear to slightly opalescent and colorless to light yellow. Any visible particles, cloudiness, or discoloration requires discarding the syringe. The FDA labeling specifies these inspection criteria explicitly. In geriatric patients with cataract or visual impairment, a second person should perform the visual check if possible.

Warming the Syringe

Remove the syringe from the refrigerator 30 minutes before injection. Cold solution increases injection-site pain and may cause the patient to flinch, raising the risk of needle movement during administration. Warming to room temperature naturally, without heating pads, microwaves, or hot water, takes approximately 20 to 30 minutes. Time this step into the caregiver's routine so it becomes automatic.

Step-by-Step Caregiver Injection Technique

The administration sequence below follows the FDA-approved prescribing information and the Amgen Evenity Instructions for Use document. Every caregiver should receive a supervised practice session with a trained nurse before the first home administration.

Site Selection and Rotation

Acceptable injection sites are the abdomen (at least 2 inches from the navel), the anterior thigh, and the outer upper arm. In patients over 65, subcutaneous tissue depth varies considerably. A 2019 study in Diabetes Technology and Therapeutics showed subcutaneous tissue thickness declines with age, particularly in the abdomen and thigh, raising the risk of intramuscular injection if needle angle is not adjusted. Use a 90-degree angle for most older adults unless subcutaneous tissue is visibly scant, in which case consult the prescribing nurse for guidance on a 45-degree approach.

Rotate sites systematically. Keep a written log with the date and site used for each of the two syringes administered that month. Never inject into skin that is bruised, red, tender, or affected by psoriasis or eczema. Rotating sites reduces local lipohypertrophy and maintains absorption consistency.

Hand Hygiene and Skin Preparation

Wash hands for a minimum of 20 seconds with soap and water. Clean the selected skin area with an alcohol swab using a circular motion and allow 30 seconds for full drying. Injecting into wet skin introduces infection risk. In geriatric patients receiving anticoagulants, apply gentle pressure with a dry gauze after removing the needle, holding for 60 seconds without rubbing, to minimize bruising.

Needle Insertion and Plunger Depression

Pinch a fold of skin at the cleaned site. Insert the needle at the correct angle in one smooth, deliberate motion. Depress the plunger slowly and steadily over approximately 5 seconds. Rushing plunger depression increases injection-site pain and can cause solution to leak back around the needle shaft. After the plunger reaches its stop, hold the needle in place for an additional 3 seconds before withdrawing, then release the skin fold.

Activate the needle safety guard immediately after withdrawal. Dispose of the used syringe in an FDA-cleared sharps container. Do not recap. Repeat the entire sequence for the second 105 mg syringe at a different site.

Cardiovascular Monitoring in Geriatric Patients

The FDA boxed warning for romosozumab specifically flags serious cardiovascular events including myocardial infarction and stroke. This warning carries extra weight in patients 65 and older, who carry higher baseline cardiovascular disease prevalence than younger adults.

Absolute Contraindication and Pre-Dose Check

Romosozumab is contraindicated in patients who have experienced a myocardial infarction or stroke within the preceding 12 months. Before each monthly dose, the caregiver should verbally confirm with the patient that no cardiac event has occurred since the last injection. Any new chest pain, sudden weakness, slurred speech, or facial drooping reported since the prior dose requires same-day physician contact before proceeding with injection.

The ARCH trial (N=4,093), published in the New England Journal of Medicine, showed numerically more serious cardiovascular adverse events in the romosozumab arm than the alendronate arm (2.5% vs. 1.9%), which drove the boxed warning. The absolute risk difference was small, but regulators judged it clinically significant given that osteoporosis patients skew elderly and often carry pre-existing cardiovascular conditions.

Blood Pressure and Pulse Monitoring at Home

Caregivers of patients with known hypertension or prior cardiac history should record blood pressure and resting pulse before each monthly administration. A systolic blood pressure above 180 mmHg or a resting pulse below 50 or above 110 beats per minute on the day of injection warrants a call to the prescribing clinician before proceeding. These thresholds are not in the FDA label but reflect standard geriatric nursing practice for biologic administration.

Hypocalcemia: Recognition and Prevention

Romosozumab transiently reduces serum calcium because increased bone formation consumes calcium rapidly. Hypocalcemia risk is highest in the first 24 to 48 hours after each injection and is amplified in older adults with reduced renal function or low dietary calcium intake.

Calcium and Vitamin D Supplementation

The FDA prescribing information states: "Ensure adequate calcium and vitamin D intake during treatment." The standard supplementation used in the FRAME trial was calcium 500 to 1,000 mg daily plus vitamin D 400 to 800 IU daily. Caregivers should confirm the patient has taken that day's calcium and vitamin D supplement before injection, not after.

Pre-existing hypocalcemia must be corrected before initiating therapy. Patients with stage 3 to 5 chronic kidney disease warrant baseline and periodic serum calcium monitoring because renal clearance of calcium is impaired. A 2020 review in the Journal of Bone and Mineral Research confirmed that hypocalcemia episodes with romosozumab clustered disproportionately in patients with creatinine clearance below 30 mL/min.

Symptoms Caregivers Must Recognize

Hypocalcemia signs in geriatric patients include muscle cramps, perioral tingling, carpopedal spasm, and confusion. Confusion is easily dismissed as baseline dementia in older adults. Any new or worsening cognitive change within 48 hours of injection should prompt a serum calcium check. Severe symptomatic hypocalcemia with tetany or seizure requires emergency evaluation.

Missed and Late Doses

What to Do When a Dose Is Delayed

Administer the missed dose as soon as it is feasible to arrange. After that injection, schedule subsequent doses from the date of the makeup dose, not from the original monthly schedule. Do not attempt to give two monthly doses within 14 days to compensate.

The FDA labeling does not specify a maximum allowable delay before skipping, but clinical pharmacists generally advise that doses delayed more than four weeks beyond the scheduled date should be discussed with the prescribing physician before administration because the drug's 6.9-day half-life means circulating levels will have declined significantly. A pharmacokinetic modeling study published in Clinical Pharmacokinetics demonstrated that romosozumab trough levels drop below 10 mcg/L by week 4, potentially reducing the sustained anabolic window.

Completing the 12-Month Course

Only 12 monthly doses are approved and clinically validated. The FRAME trial (N=7,180), published in the New England Journal of Medicine, demonstrated a 73% reduction in new vertebral fractures versus placebo at 12 months, with gains that persisted when patients transitioned to denosumab. Stopping before 12 doses truncates the anabolic phase. After the 12th dose, the prescribing clinician will transition the patient to an antiresorptive agent such as alendronate or denosumab. Failing to start antiresorptive therapy promptly after completing romosozumab leads to rapid bone density loss, a rebound phenomenon documented in a 2022 study in Bone.

Injection-Site Reactions in Older Skin

Older skin is thinner, less elastic, and more prone to bruising than younger skin. Injection-site reactions, including pain, redness, and swelling, occurred in approximately 5.1% of participants in the FRAME trial. In geriatric patients receiving concurrent anticoagulants such as warfarin or direct oral anticoagulants, local bruising can be more extensive.

Managing Bruising and Hematoma

Apply a cold pack wrapped in cloth, not directly on skin, for 5 to 10 minutes after injection if bruising develops. Avoid aspirin or ibuprofen for injection-site pain unless already prescribed, since these agents further impair platelet function. Acetaminophen 500 to 1,000 mg is an appropriate first choice for post-injection soreness in most older adults, though renal and hepatic function should be considered. If a hematoma larger than 3 cm develops or if there is expanding swelling, notify the prescriber.

When to Avoid a Scheduled Site

Inspect all potential sites before each monthly administration. Avoid any area with redness, warmth, active infection, or a healing hematoma from the prior month. In bedridden patients, the upper outer arm is often the most accessible and least traumatized site.

Sharps Disposal and Infection Control at Home

Used prefilled syringes go directly into an FDA-cleared sharps container. Never place loose needles in household trash, recycling bins, or toilet. The FDA sharps disposal guidance recommends sealing the container when it is three-quarters full and following local municipality guidelines for drop-off or mail-back programs.

For caregivers managing multiple patients or administering other injectables, label each sharps container with the patient's name to avoid mix-ups in multi-patient households or assisted living settings.

Wash hands again after completing both injections and after disposing of sharps. If a needlestick injury occurs, the caregiver should wash the wound immediately with soap and water for at least 60 seconds, then contact occupational health or a physician the same day. A CDC needlestick prevention resource provides caregiver-specific guidance.

Coordination With the Care Team

Documentation Caregivers Should Maintain

Keep a monthly injection log that records the date, time, sites used for both syringes, lot numbers from the syringe labels, any patient symptoms in the 24 hours after injection, and blood pressure and pulse if monitored. Bring this log to every physician or bone density appointment. The log helps clinicians identify dose timing gaps, site-related complications, and adherence patterns.

When to Call the Prescriber Immediately

Call the prescribing clinician on the same day if any of the following occur: the patient reports chest tightness or chest pain after injection; new unilateral weakness or facial droop develops within 48 hours; muscle spasms or perioral tingling begin within 24 hours; only one of the two syringes was administered; or a syringe was accidentally frozen and a replacement is needed before the scheduled dose date.

The Endocrine Society Clinical Practice Guideline on osteoporosis recommends that all patients receiving anabolic therapy for osteoporosis have at least one in-person clinical review within the first three months of treatment to assess tolerability, supplementation adherence, and cardiovascular status. Caregivers should ensure this appointment is scheduled before the first home-administered dose.

DXA Monitoring Schedule

A dual-energy X-ray absorptiometry (DXA) scan at baseline and again at month 12 documents the treatment response. The International Society for Clinical Densitometry recommends a minimum interval of 12 months between monitoring scans for patients on anabolic therapy. Caregivers help by scheduling the 12-month scan before the final dose is administered so results are ready when the prescriber chooses the subsequent antiresorptive agent.

Transition Planning After the 12th Dose

The 12-month romosozumab course ends abruptly. Bone mineral density gains reverse within 12 months of discontinuation without antiresorptive follow-up therapy. The ARCH trial showed that patients transitioning from romosozumab to alendronate sustained a 48% reduction in new vertebral fractures compared with alendronate alone over 24 months, per the NEJM publication. Caregivers should confirm with the prescriber, no later than month 10, which antiresorptive agent will follow and whether a prescription has been sent to the pharmacy so there is no gap between the last romosozumab dose and the first antiresorptive dose.

Denosumab (Prolia) 60 mg subcutaneous every six months is a common follow-on choice because its mechanism complements the anabolic phase. Alendronate 70 mg oral weekly is an alternative for patients without esophageal disease or severe renal impairment. The prescribing clinician makes this determination based on the patient's individual renal function, fall risk, GI tolerance, and DXA response.

In patients transitioning to denosumab, caregivers will need to learn a second injection protocol. Request a supervised training session from the specialty pharmacy or visiting nurse before the denosumab start date.